| Biologic Therapy |
1 |
1 |
| Scleroderma |
0 |
0.98 |
| Pulmonary Arterial Hypertension |
0 |
0.86 |
| Lung Fibrosis |
0 |
0.67 |
| Lung |
0 |
0.66 |
| Interstitial Lung Disease |
0 |
0.55 |
| Systemic Sclerosis |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.46 |
| Hypertension |
0 |
0.4 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.35 |
| Remission |
0 |
0.25 |
| Antineoplastic Drug |
0 |
0.2 |
| Monoclonal Antibody |
0 |
0.2 |
| Immunosuppressive Therapy |
0 |
0.16 |
| Pulmonary Hypertension |
0 |
0.16 |
| Stem Cell Research and Therapy |
0 |
0.14 |
| Europe |
0 |
0.08 |
| Raynaud Phenomenon |
0 |
0.08 |
| Rheumatoid Arthritis |
0 |
0.07 |
| Cell Transplantation |
0 |
0.06 |
| Connective Tissue Disease |
0 |
0.06 |
| Endothelin Receptor Antagonists |
0 |
0.06 |